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Concern has been raised about the potential delay in breast cancer diagnosis in the augmented breast. We linked a cohort of 2955
women, who received cosmetic breast implants in Denmark during the period 1973–1997 with the Danish Cancer Registry and the
Danish Breast Cancer Cooperative Group register. We identified 23 incident cases of invasive breast cancer diagnosed subsequent to
breast implantation. We randomly selected 11 controls for each case from the Danish Breast Cancer Cooperative Group’s register,
and obtained detailed information on all study subjects about surgery, histopathology and stage of breast cancer at diagnosis, intended
adjuvant treatment according to trial protocols and overall survival. We found that women with breast implants on average were
diagnosed with breast cancer at the same stage as controls. Significantly more women with breast implants had tumour cells in the
surgical margins according to the Danish Breast Cancer Cooperative Group’s data. There was no significant difference in overall
survival between the two groups after an average of 6.4 years of follow-up. Based on this limited number of women with breast
cancer subsequent to breast augmentation, breast implants do not appear to delay the diagnosis of breast cancer, and no evidence of
impaired survival after breast cancer diagnosis in augmented women was found.
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Breast implants are widely used for both reconstructive and
cosmetic purposes. There is no evidence that breast implants
increase the risk of breast cancer (Brinton et al, 2000b;
Mellemkjaer et al, 2000). On the contrary, several reports
document that women with cosmetic breast implants seem to be
at a lower risk of developing breast cancer (Berkel et al, 1992;
Deapen et al, 1997; McLaughlin et al, 1998; Hoshaw et al, 2001).
However, the issue of potential delay in breast cancer diagnosis in
the augmented breast has been raised, since breast implants are
radiopaque and this influences the sensitivity of mammography
(Eklund et al, 1988; Hayes et al, 1988; Silverstein et al, 1992).
Clinical reports have suggested a possible delay and difficulties in
the diagnosis of breast cancer (Leibman and Kruse, 1990;
Silverstein et al, 1990a; Carlson et al, 1993; Fajardo et al, 1995),
but most epidemiological studies have not supported a delay in
diagnosis or impaired survival among women with breast implants
(Birdsell et al, 1993; Deapen et al, 2000).
We identified all subsequent incident cases of invasive breast
cancer within a large cohort of women with breast implants. The
stage distribution at diagnosis, tumour characteristics and overall
survival of cohort women with breast cancer were compared with
those of a random sample of women with breast cancer from the
general population matched to the cohort on age and year of
diagnosis. This study entails more detailed and uniformly collected
information about tumour stage and characteristics than previous
studies.
MATERIAL AND METHODS
We have previously identified 2740 women, who underwent
cosmetic breast implantation before the age of 55 years at private
clinics and public hospitals in Denmark during 1973–1995
(Mellemkjaer et al, 2000). The women treated in the private
clinics were identified from the clinics’ files, while the women
treated in public hospitals were identified through the National
Register of Patients. For each woman, we obtained the date of
breast implantation and the Personal Identification number, a
unique 10-digit number, which encodes the date of birth and sex of
all individuals in Denmark. An additional 192 women who were
treated in private clinics during 1996–1997, and 23 women who
were over 55 years of age at implantation, were also included in the
present study, resulting in a final cohort of 2955 women with
cosmetic breast implants.
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lThe cohort was linked to the Danish Breast Cancer Cooperative
Group (DBCG) register using the Personal Identification number
to identify women with invasive breast cancer subsequent to breast
implantation. The DBCG register is a clinical database, established
in 1977 and designed primarily to evaluate the programmes for
adjuvant trials among women with primary breast cancer. The
register receives detailed information on primary surgical proce-
dure, histopathological examination, adjuvant treatment and
clinical follow-up. Based on tumour stage and menopause status,
the patients are allocated to groups with high or low risk of
recurrence, and are treated in protocols accordingly. Furthermore,
the information on patients treated outside protocol programmes
is recorded (Andersen and Mouridsen, 1988; The DBCG Secretar-
iat, 1998). A comparative study using data from both the Danish
Cancer Registry, which is the nationwide compulsory register for
all cancers established in 1943, based on reports from clinicians,
pathologists and also from death certificates (Storm et al, 1997),
and the DBCG showed highly consistent data for younger (98%)
and middle-aged (95%) women diagnosed with breast cancer,
whereas the DBCG had 21% missing cases of breast cancer for the
group over 70 years of age (Rostgaard et al, 2000).
Women with breast implants were followed for invasive breast
cancer from date of implantation or 1 January 1977, whichever
occurred last, until the age of 76 years, date of breast cancer
diagnosis, date of death, emigration, or 1 October 2001, whichever
occurred first. Computer linkage of the study cohort to the DBCG
register identified 21 women with cosmetic breast implants, who
subsequently developed breast cancer.
We also linked the implant cohort with the Danish Cancer
Registry using data available until the end of 1998. We confirmed
the 21 cases found in the DBCG and identified additionally two
women with cosmetic breast implants who were registered with
subsequent breast cancer, but who had not been reported to the
DBCG. Their medical files were obtained, and the relevant
information for this study was abstracted. Both cases were
subsequently reported to the DBCG register.
For each of the 23 breast cancer cases with cosmetic breast
implants (cases), we randomly selected 11 controls with invasive
breast cancer from the DBCG register, matched on age and
calendar year of breast cancer diagnosis 11 was the minimal
number of available individually matched controls, and conse-
quently this number of controls was chosen for each case, resulting
in a total of 253 control subjects from the background population
(controls).
Information on the following variables was obtained from the
DBCG register: date of cancer diagnosis, place of operation,
menopausal status, type of surgery and assessment of whether the
surgical margins were tumour free (side and deep margins). The
histopathological and staging variables were number of lymph
nodes removed, number of involved lymph nodes, size of tumour
(macroscopic size, evaluated by the pathologist), oestrogen- and/or
progesterone-receptor status of tumour, histological diagnosis
(WHO: ductal, lobular, tubular and medullar carcinoma or other
malignant tumours), malignancy grading of ductal carcinomas
(I–III according to mitosis activity, nuclear pleomorphy and
degree of tubule formation; I being the most benign and III the
most aggressive) and distant metastases at the time of surgery
(evaluated by clinical examination in combination with chest X-ray
and blood tests, including blood cell count and liver enzymes). The
treatment-related variables were the intended adjuvant treatment
according to trial protocols (radiotherapy, chemotherapy and
endocrine treatment).
The medical records for all the augmented breast cancer cases,
with the exception of one, which could not be found, and one
randomly selected control per case were retrieved to obtain
information on how the cancer was diagnosed, and details on the
surgical procedure including implant status. We also compared the
data reported to the DBCG register with the medical records.
Generally, there was a high level of concordance in the reported
data, but with regard to the variable ‘tumour cells in the surgical
margins’ four augmented breast cancer women were recategorised
based on the medical record information; in two cases, the biopsy
specimen had been reported instead of the final specimen, in one
case, the parameter was missing in the DBCG, but was found in the
medical record, and in the last case, there were free margins,
although narrow, and the patient was recategorised as having free
margins. None of the 23 control subjects was recategorised
regarding this variable, since there was complete agreement
between the medical records and the DBCG-data.
Statistical analyses
Frequencies were calculated for all variables. The differences
between the women with breast implants (cases) and women from
the background population (controls) in binary variables were
evaluated with w
2 tests, and crude odds ratios (OR) and
corresponding 95% confidence intervals (CI) were calculated.
The difference in tumour size between the two groups was
evaluated by analysis of variance. In order to preserve power in the
tests, the matching variables were not included as covariates,
because of the small number of breast cancer cases with cosmetic
breast implants and the large range of values of these matching
variables. All tests were performed with a 5% level of significance.
Overall survival rates, including death from all causes, were
estimated by the Kaplan–Meier method and a log-rank test was
used for comparisons between the groups. Disease-free survival
was not evaluated, as information on first recurrence was
unavailable for the seven cases and 52 controls who did not
participate in a postoperative treatment protocol.
RESULTS
In total, 23 of 2955 women (0.8%) with cosmetic breast implants
developed breast cancer after implantation. The mean age at the
time of breast cancer diagnosis among these women as well as
controls was 47.2 years, range 35–75. The mean year of cancer
diagnosis was 1993, range 1986–2000. The women had undergone
breast implantation at an average age of 38 years (range 22–61
years), yielding an average interval from implantation to breast
cancer diagnosis of 9.3 years (range 0.3–17.9 years). A total of 21
women had silicone breast implants, while implant type was
unknown for the remaining two, but they most likely also had
silicone implants, since this was the preferred implant in Denmark
during the relevant period. The majority of women in the study
were premenopausal at the time of breast cancer diagnosis, which
was to be expected in this relatively young study population. Fewer
of the cases were premenopausal compared to the controls,
although the difference was not significant (61 and 74%,
respectively, OR¼0.5; 95% CI 0.2–1.3).
As presented in Table 1, most of the tumours were ductal
carcinomas, and either receptor positive or with unknown receptor
status, with no significant differences between the two groups.
Tumour diameter tended to be larger among controls than among
cases, but the difference was not significant. Tumour dediffer-
entiation, evaluated by grade of malignancy, did not differ between
the two groups. The majority of women among both cases and
controls were treated with mastectomy, which reflected the general
treatment approach in Denmark during the period. Based on the
DBCG-data, the women with breast implants were four times more
likely than women in the control group to have tumour cells in the
surgical margins (OR¼4.2; 95% CI 1.5–11.4). Using the medical
record data on surgical margins rather than the DBCG-data altered
the statistical inference; the difference between cases and controls
diminished and became nonsignificant (OR¼2.5; 95% CI 0.8–7.3).
Lymph node dissection was performed equally between implant
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lwomen and controls. In total, 48% of the women in both groups
had regional lymph node involvement and also to a similar extent.
One patient in the implant group had distant metastases at the
time of diagnosis compared with four in the control group
(P¼0.36).
As shown in Table 2, there was no difference in intended
adjuvant treatment between the two groups. According to standard
adjuvant treatment protocols, 61% of the women with breast
implants and 69% of the controls were allocated to adjuvant
treatment (Table 2). Approximately 50% of all patients among
both cases and controls were scheduled for radiotherapy, including
those with nonradical surgical margins. There were differences,
although not significant, in systemic adjuvant treatment, with
more implant women receiving endocrine therapy and more
controls receiving chemotherapy. This pattern most likely reflects
the differences in menopausal status, which influence the choice of
treatment, since premenopausal women are more likely to receive
chemotherapy.
Table 1 Breast cancer tumour characteristics of women with cosmetic silicone breast implants prior to cancer diagnosis (cases) and breast cancer cases
from the background population (controls)
Cases (n=23) Controls (n=253)
Characteristic of woman or tumour n % n % OR (95% CI)
a
Tumour histology (WHO)
Ductal 16 70 212 84 0.5 (0.2–1.6)
b
Lobular 5 22 18 7 P=0.26
Other 0 0 18 7
Unknown 2 9 5 2
Tumour hormone-receptor status
Negative 6 26 52 21 1.7 (0.6–4.9)
Positive 10 43 148 59 P=0.32
Unknown 7 30 53 21
Tumour diameter (mm) (mean, range) 20.5 Range 9–50 25.2 Range 3–110 P=0.48
Unknown 3 13 10 4
Ductal carcinomas, malignancy grade (dedifferentiation)
Grade I 6 26 52 21 1.7 (0.6–5.0)
c
Grade II 9 39 110 43 P=0.31
Grade III 1 4 40 16
Nonductal or unknown 7 30 51 20
Breast cancer operation
Mastectomy 15 65 184 73 0.6 (0.3–1.6)
d
Lumpectomy 6 26 60 24 P=0.34
Lumpectomy followed by mastectomy 0 0 4 2
Biopsy only 2 9 5 2
Tumour cells in surgical margins (DBCG-data)
Yes 7 30 24 9 4.2 (1.5–11.4)
No 14 61 201 79 P=0.003
Unknown 2 9 28 11
Tumour cells in surgical margins (medical record information)
e
Yes 5 22 24 9 2.5 (0.8–7.3)
No 17 74 201 79 P=0.09
Unknown 1 4 28 11
Axillary surgery
Five or less lymph nodes removed 4 17 40 16 1.2 (0.4–3.6)
More than five lymph nodes removed 18 78 210 83 P=0.79
Unknown 1 4 3 1
Mean number of lymph nodes removed 11.4 Range 0–32 11.3 Range 0–31 P=0.16
Axillary lymph node metastases
Node-negative 11 48 130 51 0.9 (0.4–2.2)
Node-positive 11 48 120 47 P=0.86
Unknown 1 4 3 1
Mean number of lymph nodes affected 2.7 Range 0–20 2.2 Range 0–24 P=0.10
Women with distant metastases at time of diagnosis 1 4 4 2 P=0.36
aWomen with implants (cases) compared with women from the background population (controls). Women with missing information with regard to the variable under study
were excluded from the analysis.
bDuctal carcinomas vs all other cancers.
cMalignancy grade I vs malignancy grade II and III grouped together.
dMastectomy vs lumpectomy. In case
of conversion from lumpectomy to mastectomy, the category was mastectomy. In cases of biopsy only, the category was lumpectomy.
eBased on medical record information for
22 cases and 23 controls. For the remainder, the DBCG-data were used.
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lIn the survival analyses, the follow-up time was on average 6.4
years (range 0.3–15.7 years). Four women with breast implants
died (17%), while 66 (26%) of the control subjects died. As
illustrated in a Kaplan–Meier plot (Figure 1), the 5-year survival
estimate for implant women is 86% compared with 78% among the
controls (P¼0.36). The medical records stated that in 13 (57%) of
the 23 breast cancer cases with implants, the implant was removed
during the cancer surgery and in eight women (35%) it was left in
situ. In one case, the implant had been removed prior to the cancer
diagnosis, and in another case the medical records could not be
traced. All five of the implant women who, according to the
medical records, had tumour cells in the surgical margins were
treated with mastectomy, and four of them also had explantation;
for the last case this information was not available. The nonradical
margins were found in the final mastectomy-specimen, and the
women accordingly received postoperative adjuvant radiotherapy.
Two of the implant women were treated with skin-sparing
mastectomy, one kept her implant and the other was reconstructed
with an immediate TRAM flap, but neither of these patients was
among those with nonradical margins.
From the medical records we ascertained that 16 (70%) of the
implant women discovered the tumour themselves. The remaining
were diagnosed as follows: two were diagnosed clinically by
physicians during diagnostic work-up because of other diseases,
one was found by a plastic surgeon in a consultation related to
capsular contracture, two were diagnosed after a biopsy performed
during an operation for a presumed breast infection, and two were
unknown. An equal proportion of the control subjects whose
medical records were retrieved had found the tumour themselves.
None of the augmented women with breast cancer and a potential
maximum of five controls participated in mammography screen-
ing for breast cancer, evaluated by knowledge of the mammo-
graphy screening centres active in the relevant areas and calendar
period.
DISCUSSION
The results of our study of breast cancer among women with
cosmetic breast implants indicate that the cancer was not
diagnosed later or at a more advanced stage than in the normal
population. The women with augmented breasts in our study did
not differ from controls with regard to relevant tumour
characteristics at diagnosis. More of the women with implants
had tumour cells in the surgical margins, but we observed no
evidence of an unfavourable survival within our rather limited
follow-up time.
Clinical case series have reported a tendency towards a delayed
breast cancer diagnosis among women with breast implants
(Gottlieb et al, 1984; Leibman and Kruse, 1990; Silverstein et al,
1990a; Carlson et al, 1993; Fajardo et al, 1995). Overall,
epidemiological studies have not been able to confirm such
reports. Two large cohort studies (Birdsell et al, 1993; Deapen et al,
2000), which compared breast implant women with breast cancer
Table 2 Adjuvant treatment according to DBCG-protocols of women with cosmetic silicone breast
implants prior to cancer diagnosis (cases) and women from the background population (controls)
Cases (n=23) Controls (n=253)
Adjuvant treatment according to protocol
a n % n % OR (95% CI)
b
Subsequent adjuvant treatment (any)
No 6 26 63 24 1.2 (0.4–3.2)
Yes 14 61 175 69 P=0.73
Unknown 3 13 15 6
Subsequent chemotherapy
No 11 48 98 39 2.3 (0.8–6.9)
Yes 5 22 103 41 P=0.12
Unknown 7 30 52 21
Subsequent endocrine therapy
No 11 48 157 62 0.6 (0.2–1.9)
Yes 5 22 44 17 P=0.39
Unknown 7 30 52 21
Subsequent radiotherapy
No 10 43 129 51 0.8 (0.3–1.8)
Yes 12 52 119 47 P=0.56
Unknown 1 4 5 2
aSee The DBCG Secretariat (1998).
bWomen with implants (cases) compared with women without implants (controls).
Women with missing information with regard to the variable under study were excluded from the analysis.
%
100
80
60
40
20
0
02468 1 0
Years
Cases
Controls
Figure 1 Overall survival after breast cancer in 23 women with cosmetic
breast implants prior to cancer diagnosis (cases) and 253 breast cancer
cases from the background population (controls).
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lto breast cancer cases in the background population, reported
findings similar to ours. There were no significant differences with
regard to stage of disease at diagnosis or survival. Information on
the cases and controls was obtained from medical records and
cancer registers, respectively, so information bias cannot be ruled
out. Also in concordance with our findings, a clinical study (Cahan
et al, 1995) comparing 22 augmented breast cancer patients with
all other breast cancer patients in the same surgical clinic found no
differences in stage of disease at diagnosis. It was concluded that
nonpalpable and preinvasive breast cancer can be detected in the
augmented patient. A similar study (Clark et al, 1993) of all breast
cancer cases in augmented women diagnosed at the study clinic
found that augmented women tended to have smaller tumours and
more often their tumours were diagnosed at physical examination
(by themselves or their physician) than other breast cancer
patients diagnosed at the clinic. Significantly fewer of the
augmented women had nodal involvement (19 vs 41% in the
comparison group). However, in both the above studies, it was not
stated how the patients were referred to the clinic, and selection
bias may have influenced the results. In another cohort study
(Brinton et al, 2000b), 78 cases of breast cancer in women with
breast implants were compared with breast cancer cases in a
control cohort of women who had undergone other kinds of
cosmetic surgery. A tendency towards more advanced stages in
cases compared with controls was reported. However, the
differences were not statistically significant. As in our study, no
differences in overall survival were noted.
The presence of breast implants, silicone or saline, makes
mammography more difficult (Gumucio et al, 1989). The implant
obscures some of the parenchyma, and breasts with subglandular
positioned implants with capsular contracture are the most
difficult to examine (Carlson et al, 1993). Specific techniques have
been developed to increase the efficacy of mammography among
augmented women (Eklund et al, 1988). A methodological study
(Silverstein et al, 1990b) compared preoperative mammograms
with postaugmentation mammograms in 62 healthy women, and
found that the implants obscured from 9 to 44% of the glandular
tissue, depending on implant location, mammography view and
technique. Obtaining a baseline mammography prior to and
perhaps even after implantation has been recommended (Leibman
and Kruse, 1990; Silverstein et al, 1992).
Overall, the results of the above mammographic and epidemio-
logical studies point in different directions regarding delayed
breast cancer diagnosis among implanted women. Since most of
the women in our study found the tumour themselves, a potential
impairment of mammography could not be evaluated. It is
possible that in a population of women undergoing regular breast
cancer screening with mammography, women with breast implants
could be diagnosed at a later state than women without implants.
None of the studies to date has sufficient data to answer this
question. However, the presence of breast implants, especially
submuscularly positioned implants, often makes both clinical
examination and self-examination of the breast tissue easier, since
the glandular tissue can be palpated against a firm background,
and this may account for the lack of delay in diagnosis (Clark et al,
1993). Women who receive breast implants tend to focus on health
issues and be self-attentive (Anderson, 1998), and to have less
breast tissue, thus probably making them more likely to find a
breast tumour even at an early stage.
Both cases and controls in our study received on average the
same surgical and adjuvant treatment. However, more implant
women had residual tumour cells in the surgical margins, even
though this excess was not statistically significant when based on
information from the medical records. Medical record information
is likely to be more complete than the DBCG register data, but was
only obtained for a small subset of the controls, and this could
introduce selection bias. If we had reviewed the medical records
from all the background controls, which was not feasible because
of problems with the availability of the records, we may have
encountered controls who would qualify for reclassification, and
this could have affected our calculations in an unknown direction.
We had an a priori expectation that women with implants would
be more likely to request breast preservation than other women
and speculated that this could account for the excess of
women with nonradical margins. However, similar proportions
of women in the two groups were treated with mastectomy,
including all the women with nonradical margins. Free surgical
margins are a strong predictor of both local control of the disease
and survival (Clemons et al, 2001; Medina-Franco et al, 2002);
however, cases did not have a poorer survival than controls. The
average follow-up time of 6.4 years is limited with respect to
evaluating survival, since death from breast cancer can occur
several years after the cancer diagnosis, and the study population
is small, so the results should be interpreted with caution. To our
knowledge, no other study has reported on the risk of nonradical
tumour resection among women with breast implants, and this
issue needs further attention.
We found few cases of breast cancer in the cohort of women
with cosmetic breast implants. Previous findings based on the
same cohort (Mellemkjaer et al, 2000) identified 16 cases of breast
cancer among 2740 women with cosmetic breast implants under 55
years of age. Compared to the 17.3 expected cases, this yielded a
standardised incidence ratio (SIR) of 0.9 (95% CI 0.5–1.5). Others
have reported similar findings and concluded that women with
cosmetic breast implants are not at increased risk of subsequent
breast cancer (Berkel et al, 1992; Deapen et al, 1997; McLaughlin
et al, 1998; Brinton et al, 2000b); on the contrary, a recent meta-
analysis reported a 30% reduction of breast cancer risk among
women with breast implants (RR¼0.72; 95% CI 0.61–0.85) and it
was concluded that breast implants may confer a protective effect
against breast cancer (Hoshaw et al, 2001). Several explanations
for this protective effect have been put forward: activation of the
immune response as result of foreign body reaction may enhance
detection and degradation of precancerous lesions; compression of
the glandular tissue from the implant may diminish blood
perfusion, which may alter cellular metabolism, and a local
decrease in body temperature caused by the implant could
diminish cellular metabolism (Deapen et al, 1997; Brinton et al,
2000b; Hoshaw et al, 2001). However, different preoperative
characteristics among women seeking breast implantation com-
pared with other women could perhaps more likely account for the
decreased breast cancer risk among implant women. This includes
less use of oral contraception (Kjøller et al, 2003), less alchohol use
(Fryzek et al, 2000; Kjøller et al, 2003), lower age at first birth,
higher parity, and lower BMI (Cook et al, 1997; Brinton et al,
2000a; Fryzek et al, 2000; Kjøller et al, 2003). Amount of glandular
tissue may also play a role although this has been highly debated,
mostly because of the problems of evaluating the true glandular
mass of the breast (Hsieh and Trichopoulos, 1991; Tavani et al,
1996; Thurfjell et al, 1996; Egan et al, 1999) However, in both
Swedish and Danish investigations of women who underwent
breast reduction surgery, large statistically significant reduction in
breast cancer incidence of 30–50% were observed, respectively
(Boice et al, 1997, 2000). In a recent study based on the same
Swedish cohort of women with breast hypertrophy, a reduction in
breast cancer risk proportionate to the amount of resected breast
tissue was reported (Brinton et al, 2001). These studies support the
concept of the amount of breast tissue being a risk factor in breast
cancer.
The primary limitations of our study are the small number of
breast cancer cases among augmented women and the relatively
short follow-up time, which suggest that survival estimates be
interpreted with caution. Potential bias exists, since more
augmented breast cancer cases were treated outside adjuvant
protocols, and there may be differences in the quality of
information between the two groups, which thus may not be as
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lcomparable as intended. However, since information was sampled
from the same registries, this potential bias is less of a concern
than in other studies in which different data sources were used.
The strengths of this study include the ability to have virtually
complete follow-up of a well-defined cohort of women with
cosmetic breast implants and to obtain highly detailed clinical and
staging information for both cases and controls from the DBCG-
register, which permitted evaluation of numerous important
tumour- and treatment-related parameters. In addition, linkage
with the Danish Cancer Register allowed complete ascertainment
of all breast cancer cases.
In conclusion, the present study suggests, consistent with several
other epidemiological studies, that the stage of breast cancer at
diagnosis in breast-implanted woman does not appear to be
more advanced compared with age- and calendar-matched
controls, indicating that the diagnosis is not meaningfully delayed
because of the implants, and that overall survival appears not
to be influenced by the presence of implants. We suggest that the
issue of nonradical surgical margins be investigated in future
studies.
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